TICKERNERD
Menu
GLSIGLSIHealthcare · Biotechnology

GLSI Stock Forecast: Greenwich LifeSciences, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$17
+8.72% on the day

The 2 Wall Street analysts covering Greenwich LifeSciences, Inc. hold a median 12-month price target of $57 — +242.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 41 of 100 as at 22 Aug 2026 — in the lower half.

Market cap
$244.3M
Ticker Nerd rank
41 / 100
Median analyst target
$57
Analysts covering
2
Total return, dividends reinvested
1W
−0.9%
1M
+13.6%
YTD
−20.8%
1Y
+40.5%
From 52W high
−50.4%
From 52W low
+112.0%
$8
$34
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

GLSI stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Greenwich LifeSciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
41 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
86
Size
66
Accruals
61
Momentum
51
Issuance
43
Revisions
41
Growth
41
Volatility
31
Quality
13

Value (86): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Quality (13): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

GLSI stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on GLSI, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$20$40$60$80Oct 25Jan 26Apr 26Jul 26GLSIHigh $69Median $57Low $45

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says2 analysts
2 Buy0 Hold0 Sell
Low $45Median $57High $69

The green dot is the last close — the median target sits +242.4% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
21 July 2026HC Wainwright & Co.MaintainsBuy$50 → $69
30 Dec 2025HC Wainwright & Co.MaintainsBuy$39 → $50
30 Dec 2025HC Wainwright & Co.MaintainsBuy—
21 Apr 2025HC Wainwright & Co.MaintainsBuy—
11 Feb 2025HC Wainwright & Co.ReiteratesBuy—
23 Aug 2024HC Wainwright & Co.MaintainsBuy—
22 May 2024HC Wainwright & Co.ReiteratesBuy—
28 Feb 2024HC Wainwright & Co.ReiteratesBuy—
20 Feb 2024HC Wainwright & Co.MaintainsBuy—
10 Apr 2023HC Wainwright & Co.ReiteratesBuy—
1 Sept 2021HC Wainwright & Co.InitiatesBuy—
27 Jan 2021Aegis CapitalInitiatesBuy—
26 Jan 2021Aegis CapitalInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. GLSI appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

GLSI analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Greenwich LifeSciences, Inc. (GLSI) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−11.6×

Cheaper than 93% of US stocks

Price / sales
—
Price / book
46.4×

Cheaper than 2% of US stocks

EV / EBITDA
−9.5×

Cheaper than 83% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−986.3%

Higher than 1% of US stocks

Return on assets
−236.0%

Higher than 1% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

GLSI vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
GLSIGreenwich LifeSciences, Inc.$244.3M
41
DTILPrecision BioSciences, Inc.$244.3M
70
CGENCompugen Ltd.$247.3M
82
CNXUConexeu Sciences, Inc.$237.9M
2
SIONSionna Therapeutics, Inc.$236.1M
32
NAGENiagen Bioscience, Inc.$254.0M
54
SLGLSol-Gel Technologies Ltd.$254.1M
45

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Greenwich LifeSciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest GLSI news & analysis

Greenwich LifeSciences Extends Lock-up of Directors and Officers to January 31, 2027

GlobeNewsWire · 10 Aug 2026neutral

Greenwich LifeSciences' Board of Directors extended the lock-up on shares held by its directors, officers, and certain pre-IPO investors to January 31, 2027, about 76 months from the company's IPO. During this period those individuals cannot sell their common stock unless the Board modifies the arrangement, and after the date sales will be restricted under a leak-out plan.

Why it matters — GLSI watchers may care because it signals the company's leadership and pre-IPO investors will hold their shares for an extended period before any restricted selling could begin.

FAQ

Frequently asked questions about GLSI stock

What is the GLSI stock price forecast for 2026-2027?

The 2 Wall Street analysts covering Greenwich LifeSciences, Inc. have a median 12-month price target of $57, with estimates ranging from $45 to $69. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is GLSI stock a buy right now?

Of the 2 analysts covering Greenwich LifeSciences, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Greenwich LifeSciences, Inc. 41 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank GLSI?

As at 22 Aug 2026, Greenwich LifeSciences, Inc. ranks 41 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (86 of 100).

Will GLSI stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +242.4% from the last close, and Ticker Nerd's factor model ranks Greenwich LifeSciences, Inc. 41 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the GLSI stock forecast for 2030?

No analyst covering Greenwich LifeSciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GLSI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $45 to $69 over the next 12 months.

How has GLSI stock performed over the past year?

Greenwich LifeSciences, Inc. returned +40.5% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Greenwich LifeSciences, Inc. do?

Greenwich LifeSciences Inc. is a clinical-stage biopharmaceutical company focused on developing novel cancer immunotherapies targeting breast cancer and other HER2/neu-expressing cancers.

What is the latest news on GLSI?

The most recent item we track (GlobeNewsWire, 10 Aug 2026): "Greenwich LifeSciences Extends Lock-up of Directors and Officers to January 31, 2027". Greenwich LifeSciences' Board of Directors extended the lock-up on shares held by its directors, officers, and certain pre-IPO investors to January 31, 2027, about 76 months from the company's IPO. During this period those individuals cannot sell their common stock unless the Board modifies the arrangement, and after the date sales will be restricted under a leak-out plan.

Company

About Greenwich LifeSciences, Inc.

Greenwich LifeSciences Inc. is a clinical-stage biopharmaceutical company focused on developing novel cancer immunotherapies targeting breast cancer and other HER2/neu-expressing cancers. Its lead product candidate, GP2, is a nine-amino acid peptide derived from the HER2/neu protein, combined with GM-CSF to form GLSI-100, designed to prevent breast cancer recurrences in patients who have undergone surgery and standard treatments like trastuzumab. The company is advancing GLSI-100 through the Flamingo-01 Phase III clinical trial, a global, randomized, double-blinded study enrolling up to 750 high-risk HER2-positive patients across approximately 150 sites in the United States and Europe, in collaboration with leading oncology networks and institutions. This immunotherapy aims to activate the immune system against HER2/neu-expressing tumor cells, addressing an unmet need in preventing recurrence for patients where existing therapies fall short. Founded in 2006 and headquartered in Stafford, Texas, Greenwich LifeSciences Inc. operates in the biotechnology sector, emphasizing peptide-based vaccines for oncology applications.

CEO Mr. Snehal S. Patel · 4 employees · United States · https://greenwichlifesciences.com